Pinpointing new forms of the coronavirus could be vital, particularly if it mutates in response to vaccination, the company says.
The pandemic provided the best and worst of times for smid-cap medtechs.
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
The group has blamed placebo “overperformance” on a high proportion of less-sick patients.
Trial results in Covid-19 and cancer emerge, but little promise is seen.
An extraordinary meeting of the EU CHMP recommends conditional approval of Pfizer/Biontech’s Covid-19 vaccine.
Pinpointing new forms of the coronavirus could be vital, particularly if it mutates in response to vaccination, the company says.
The pandemic provided the best and worst of times for smid-cap medtechs.
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
The group has blamed placebo “overperformance” on a high proportion of less-sick patients.
Trial results in Covid-19 and cancer emerge, but little promise is seen.
An extraordinary meeting of the EU CHMP recommends conditional approval of Pfizer/Biontech’s Covid-19 vaccine.